Q-Line Biotech's reagent shift lifts gross margin 750 bps, targets 30-35% growth
FY26 gross margin hits 60.8% as manufactured reagents replace imports; FY27 guidance backed by 300-400 new analyzer installations and ₹10 cr CDMO target.
What's new
- FY26 revenue up 9% to ₹341.7 cr, gross margin up 750 bps to 60.8%.
- FY27 revenue growth guided at 30-35%, with 300-400 new analyzer installations planned.
- Lucknow Unit 4 operational; can support 3-4x current reagent business without new capex.
Why this matters
The 750 bps gross margin gain to 60.8% confirms the shift to manufactured reagents is working. FY27 guidance is ambitious but backed by specific drivers: recurring revenue from 1,550+ analyzers and a ₹10 cr CDMO target. The main risk remains geographic concentration with 77% of revenue from Uttar Pradesh.
What we're watching
- Progress on 300-400 new analyzer installations and reagent revenue per device.
- International expansion in Middle East and Africa via Dubai manager and partnerships.
- Whether CDMO and export targets materialize and reduce geographic concentration.
The full read
Q-Line's FY26 results show a clear shift: gross margin climbed 750 bps to 60.8%, the new Lucknow Unit 4 can support 3-4 times current reagent business without new capex, and the installed base of 1,550+ Selectra Pro M analyzers generates ₹25,000–30,000 per month per device in reagent revenue. FY27 guidance of 30–35% revenue growth is backed by specific drivers: 300-400 new analyzer installations, ₹6 cr in exports, and a ₹10 cr CDMO target. The company is reducing its reliance on Uttar Pradesh, which still accounts for 77% of revenue, aiming for a 50-50 B2G/trade mix by FY28. The next test: execution on international expansion and CDMO timelines.
Questions answered
- What drove the 750 bps increase in gross margin in FY26?
- A shift to higher-margin manufactured reagents replaced imported alternatives, lifting gross margin from 53.3% to 60.8%.
- How much recurring revenue does each installed analyzer generate?
- The 1,550+ installed Selectra Pro M analyzers generate ₹25,000–30,000 per month in reagent consumption per device, creating a predictable revenue stream.
- What is the capacity unlock from the new Lucknow Unit 4 facility?
- The facility is operational and can support 3-4 times the current reagent business without requiring additional capital expenditure.
- What are Q-Line's international expansion plans?
- The company has appointed a Dubai-based manager, formed distributor partnerships in the Middle East and Africa, and aims for ₹6 cr in exports in FY27.
- What is the CDMO opportunity and its status?
- Q-Line has a ₹10 cr CDMO target for FY27 and has completed tech transfer with a European partner.
- Why is geographic concentration a risk for Q-Line?
- Uttar Pradesh accounts for 77% of revenue. Management plans to reduce this to a 50-50 mix between B2G and trade by FY28.